Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ARS Pharmaceuticals Inc shares valued at $240,000 were sold by Karas Eric on Jun 18 ’25. At $16.00 per share, Karas Eric sold 15,000 shares. The insider’s holdings dropped to 7,696 shares worth approximately $0.14 million following the completion of this transaction.
Also, ERIC KARAS purchased 15,000 shares, netting a total of over 240,000 in proceeds.
Before that, Fitzpatrick Alexander A had sold 102,969 shares from its account. In a trade valued at $1,451,513, the Chief Legal Officer traded ARS Pharmaceuticals Inc shares for $14.10 each. Upon closing the transaction, the insider’s holdings decreased to 102,969 shares, worth approximately $1.62 million.
As published in their initiating research note from Scotiabank on March 07, 2025, ARS Pharmaceuticals Inc [SPRY] has been a Sector outperform and the price target has been revised to $30. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of August 20, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for SPRY. Earlier on August 13, 2024, Raymond James upgraded its rating. Their new recommendation was “a Strong buy” for SPRY stock which previously was a “an Outperform”.
Analyzing SPRY Stock Performance
On last trading session,, ARS Pharmaceuticals Inc [NASDAQ: SPRY] rose 4.75% to $18.08. The stock’s lowest price that day was $17.2725, but it reached a high of $18.21 in the same session. During the last five days, there has been a surge of approximately 13.64%. Over the course of the year, ARS Pharmaceuticals Inc shares have jumped approximately 119.42%. Shares of the company reached a 52-week high of $18.21 on 06/26/25 and a 52-week low of $10.00 on 03/04/25.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 17.50, which, if violated, would cause prices to drop to 16.92. In the upper region, resistance lies at 18.44. The next price resistance is at 18.79. RSI (Relative Strength Index) is 73.36 on the 14-day chart, showing overbought technical sentiment.
Is ARS Pharmaceuticals Inc subject to short interest?
Stocks of ARS Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.65 million shares to 16.58 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 18.23 million shares. A decline of -9.98% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.13 of the overall float, the days-to-cover ratio (short ratio) decline to 12.13.
Which companies own the most shares of ARS Pharmaceuticals Inc (SPRY)?
In terms of ARS Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 27.46% from the previous closing price of $17.26. Analysts anticipate ARS Pharmaceuticals Inc stock to reach 30 by 2025, with the lowest price target being 18. In spite of this, 4 analysts ranked ARS Pharmaceuticals Inc stock as Buy at the end of 2025. On August 12, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and reiterated coverage with a $20.
